Cartesian Therapeutics
RNAC · NASDAQ
$6.40+$0.315 (+5.18%)TodayMarket closed ·
Prev close $6.08
EPS: actual vs estimate
Beat the estimate in 4 of the last 8 quarters, by 90.6% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.8859 | $0.61 | +168.9% |
| Q1 FY26 | -$0.901 | -$1.46 | −62.0% |
| Q4 FY25 | -$0.8704 | -$3.57 | −310.2% |
| Q3 FY25 | -$0.8619 | -$1.38 | −60.1% |
| Q2 FY25 | -$0.8262 | $0.50 | +160.5% |
| Q1 FY25 | -$0.7198 | -$0.68 | +5.5% |
| Q4 FY24 | -$0.816 | -$0.59 | +27.7% |
| Q3 FY24 | -$0.9282 | -$1.13 | −21.7% |
Earnings calls
- 25th Annual Needham Virtual Healthcare Conference
- Morgan Stanley 23rd Annual Global Healthcare Conference
- Special Call - Cartesian Therapeutics, Inc.
- 2024 Cantor Fitzgerald Global Healthcare Conference
- H.C. Wainwright 26th Annual Global Investment Conference 2024
- Special Call - Cartesian Therapeutics, Inc.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.